insights.citeline.com Open in urlscan Pro
2600:1408:c400:27::17da:daab  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Sign In

Free Trial

Sign In

Free Trial

Search

Search

--------------------------------------------------------------------------------

Scrip

--------------------------------------------------------------------------------

Scrip Perspectives

--------------------------------------------------------------------------------

Scrip Asks

--------------------------------------------------------------------------------

Focus On Asia
Scrip Asia 100

--------------------------------------------------------------------------------

Market Snapshot

--------------------------------------------------------------------------------

Business
Deals
Financing
Earnings
Start-Ups & SMEs
Stock Watch

--------------------------------------------------------------------------------

Leadership
Executives On The Move
Interviews

--------------------------------------------------------------------------------

R&D
Clinical Trials
Pipeline Watch

--------------------------------------------------------------------------------

New Products

--------------------------------------------------------------------------------

Therapy Areas

--------------------------------------------------------------------------------

Advanced Therapies

--------------------------------------------------------------------------------

Digital Technologies
AI

--------------------------------------------------------------------------------

Rare Diseases

--------------------------------------------------------------------------------

Women's Health

--------------------------------------------------------------------------------

Drug Pricing

--------------------------------------------------------------------------------

ESG

--------------------------------------------------------------------------------

Conferences
J.P. Morgan
BIO
ASCO
ESMO
Bio-Europe

--------------------------------------------------------------------------------

Podcasts

--------------------------------------------------------------------------------

Partnered Content
 1. Scrip
 2. >>Conferences


NOVO NORDISK’S SEMAGLUTIDE TOPS MADRIGAL’S REZDIFFRA IN NASH


GREATER COMBINED EFFECT SEEN IN PHASE III TRIALS

19 Nov 2024 
• By Joseph Haas

The firm revealed that an analysis of its Phase III ESSENCE trial combining
fibrosis reduction and NASH resolution showed a higher effect over placebo than
in Madrigal’s pivotal trial.


Novo Nordisk presented more data for semaglutide in NASH at AASLD (Shutterstock)

New data from Novo Nordisk’s Phase III ESSENCE study of semaglutide in
non-alcoholic steatohepatitis (NASH) unveiled at the American Association for
the Study of Liver Disease conference on 19 November showed that the GLP-1
agonist performed better than Madrigal’s Rezdiffra (resmetirom), the only
approved NASH drug, in an analysis combining outcomes on the two primary
endpoints, reduction of liver fibrosis and resolution of NASH.


NEW TO SCRIP?

Start a Free Trial

Already subscribed? Log in

Ask The AnalystDownloadBookmark


RELATED COMPANIES

--------------------------------------------------------------------------------


NOVO NORDISK A/S


MADRIGAL PHARMACEUTICALS, INC.


VIKING THERAPEUTICS, INC.


AKERO THERAPEUTICS, INC.


89BIO, INC.




MORE FROM CONFERENCES


ASH: HOW SHOULD BCMA-DIRECTED BISPECIFICS FIT INTO MYELOMA TREATMENT?

17 Dec 2024 
• By Alaric DeArment

With two products on the market, a third on the way and a fourth under
development too, the question becomes how they will fit in relative to each
other and also CAR-T cell therapies.


ASH: OUT WITH THE OLD, IN WITH THE NEW AS BMS USHERS IN CELMOD CLASS

16 Dec 2024 
• By Alaric DeArment

BMS presented Phase I/II data for its next-generation small molecule drugs
mezigdomide and iberdomide at ASH.


ASH: SICKLE CELL TREATMENT DECISIONS IN THE POST-OXBRYTA, GENETIC MEDICINE ERA

15 Dec 2024 
• By Mandy Jackson

Hematologists discussed the still limited treatment options for sickle cell
disease at ASH, weighing the risks and benefits of disease-modifying versus
curative therapies after the withdrawal of Pfizer’s Oxbryta (voxelotor).


ASH: PFIZER SEES CD70-TARGETED MDS DRUG AS BETTER FOR FRAILER PATIENTS

13 Dec 2024 
• By Alaric DeArment

The drug maker presented Phase I data for PF-08046040 at ASH, having designed it
to avoid some of the toxicities associated with antibody-drug conjugates.

See More

--------------------------------------------------------------------------------


MORE FROM ALIMENTARY/METABOLIC


STOCK WATCH: US ELECTION BRINGS MORE CONS THAN PROS FOR LIFE SCIENCES

10 Dec 2024 
• By Andy Smith

The US election result brought stock market volatility especially to pharma and
biotech companies but the poster children for approved GLP-1 agonists and
vaccines were initially the hardest hit.


BIOAGE’S HOPES FOR COMBO OBESITY DRUG DIM DUE TO LIVER SAFETY

09 Dec 2024 
• By Jessica Merrill

The company discontinued the Phase II STRIDES study testing azelaprag as
monotherapy and in combination with Lilly’s tirzepatide in obesity.


LILLY’S HEAD-TO-HEAD TRIAL REAFFIRMS ZEPBOUND EFFICACY VERSUS WEGOVY

04 Dec 2024 
• By Jessica Merrill

Zepbound led to greater weight loss versus Wegovy in a Phase III trial,
bolstering its position as the superior product in the fast-growing obesity
space.

See More
Twitter feedRSS feedRSS feed

 * About UsOpens in new window
 * Meet the TeamOpens in new window
 * RSS FeedOpens in new window

 * Contact Us
 * Customer Service
 * SubscribeOpens in new window
 * AdvertisingOpens in new window
 * Feedback

Home

--------------------------------------------------------------------------------

Terms and ConditionsOpens in new window

--------------------------------------------------------------------------------

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company
Pharma Intelligence UK Limited is a company registered in England and Wales with
company number 13787459 whose registered.





search by queryly Advanced Search

Cookies Button


ABOUT COOKIES ON THIS SITE

We and our partners use cookies to enhance your website experience, learn how
our site is used, offer personalised features, measure the effectiveness of our
services, and tailor content and ads to your interests while you navigate on the
web or interact with us across devices. For more information see our Privacy
Policy.
Settings



PRIVACY PREFERENCE CENTER

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more and change our default settings.
However, blocking some types of cookies may impact your experience of the site
and the services we are able to offer.
More information


MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will not then work.
These cookies do not store any personally identifiable information.

FUNCTIONAL COOKIES

Functional Cookies

These cookies enable the website to provide enhanced functionality and
personalisation. They may be set by us or by third party providers whose
services we have added to our pages. If you do not allow these cookies then some
or all of these services may not function properly.

PERFORMANCE COOKIES

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. All
information these cookies collect is aggregated and therefore anonymous. If you
do not allow these cookies we will not know when you have visited our site, and
will not be able to monitor its performance.

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.

Back Button


COOKIE LIST



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Confirm My Choices